Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Cue Biopharma Inc diskutieren

Cue Biopharma Inc

WKN: A2JAT5 / Symbol: CUE / Name: Cue Biopharma / Aktie / Small Cap /

0,86 €
0,58 %

Einschätzung Buy
Rendite (%) -42,17 %
Kursziel 9,27
Veränderung
Endet am 22.03.24

Cue Biopharma, Inc. (NASDAQ: CUE) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
Ratings data for CUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -42,17 %
Kursziel 7,41
Veränderung
Endet am 22.03.24

Cue Biopharma, Inc. (NASDAQ: CUE) had its price target lowered by analysts at Stifel Nicolaus from $9.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for CUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -63,93 %
Kursziel 7,45
Veränderung
Endet am 06.11.24

Cue Biopharma, Inc. (NASDAQ: CUE) had its price target raised by analysts at Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.
Ratings data for CUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -56,32 %
Kursziel 5,48
Veränderung
Endet am 13.03.25

Cue Biopharma, Inc. (NASDAQ: CUE) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
Ratings data for CUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -48,19 %
Kursziel 7,39
Veränderung
Endet am 03.04.25

Cue Biopharma, Inc. (NASDAQ: CUE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $8.00 price target on the stock.
Ratings data for CUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -47,88 %
Kursziel 9,19
Veränderung
Endet am 09.04.25

Cue Biopharma, Inc. (NASDAQ: CUE) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
Ratings data for CUE provided by MarketBeat

Einschätzung Buy
Rendite (%) -47,88 %
Kursziel 7,35
Veränderung
Endet am 09.04.25

Cue Biopharma, Inc. (NASDAQ: CUE) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $8.00 price target on the stock.
Ratings data for CUE provided by MarketBeat